June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361–5.
Google Scholar
Lim WA, June CH. The principles of engineering immune cells to treat cancer. Cell. 2017;168:724–40.
Google Scholar
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17.
Google Scholar
Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 2022;602:503–9.
Google Scholar
Van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, et al. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood. 2023;141:756–65.
Google Scholar
Park JH, Rivière I, Gonen M, Wang X, Sénéchal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59.
Google Scholar
Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024;390:584–6.
Google Scholar
Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024;30:338–41.
Google Scholar
Park S, Pascua E, Lindquist KC, Kimberlin C, Deng X, Mak YSL, et al. Direct control of CAR T cells through small molecule-regulated antibodies. Nat Commun. 2021;12:710.
Google Scholar
Doan AE, Mueller KP, Chen AY, Rouin GT, Chen Y, Daniel B, et al. FOXO1 is a master regulator of memory programming in CAR T cells. Nature. 2024;629:211–8.
Google Scholar
Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD Jr., et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44:380–90.
Google Scholar
van den Broek T, Borghans JAM, van Wijk F. The full spectrum of human naive T cells. Nat Rev Immunol. 2018;18:363–73.
Google Scholar
Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, et al. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9:116.
Google Scholar
Lopresti L, Tatangelo V, Baldari CT, Patrussi L. Rewiring the T cell-suppressive cytokine landscape of the tumor microenvironment: a new frontier for precision anti-cancer therapy. Front Immunol. 2024;15:1418527.
Google Scholar
Triplett TA, Garrison KC, Marshall N, Donkor M, Blazeck J, Lamb C, et al. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nat Biotechnol. 2018;36:758–64.
Google Scholar
Wittibschlager V, Bacher U, Seipel K, Porret N, Wiedemann G, Haslebacher C, et al. CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma. Int J Mol Sci. 2023;24:5688.
Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, et al. Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study. Lancet. 2023;402:641–54.
Google Scholar
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139.
Google Scholar
Derigs P, Schubert ML, Dreger P, Schmitt A, Yousefian S, Haas S, et al. Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study. Leukemia. 2024;38:2419–28.
Google Scholar
Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24:563–71.
Google Scholar
Liang EC, Albittar A, Huang JJ, Hirayama AV, Kimble EL, Portuguese AJ, et al. Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL. Blood Adv. 2023;7:6990–7005.
Google Scholar
An N, Li J, Luo P, Wang D, Zhang P, Shu C, et al. Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma. J Transl Med. 2025;23:552.
Google Scholar
Tantalo DG, Oliver AJ, von Scheidt B, Harrison AJ, Mueller SN, Kershaw MH, et al. Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies. J Immunother Cancer. 2021;9:e002555.
Chan JD, Lai J, Slaney CY, Kallies A, Beavis PA, Darcy PK. Cellular networks controlling T cell persistence in adoptive cell therapy. Nat Rev Immunol. 2021;21:769–84.
Google Scholar
Berard M, Tough DF. Qualitative differences between naïve and memory T cells. Immunology. 2002;106:127–38.
Google Scholar
Klebanoff CA, Gattinoni L, Palmer DC, Muranski P, Ji Y, Hinrichs CS, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res. 2011;17:5343–52.
Google Scholar
Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA. 2005;102:9571–6.
Google Scholar
Lugli E, Galletti G, Boi SK, Youngblood BA. Stem, effector, and hybrid states of memory CD8(+) T cells. Trends Immunol. 2020;41:17–28.
Google Scholar
Knörck A, Schäfer G, Alansary D, Richter J, Thurner L, Hoth M, et al. Cytotoxic efficiency of human CD8(+) T cell memory subtypes. Front Immunol. 2022;13:838484.
Google Scholar
Kwiecień I, Rutkowska E, Sokołowski R, Bednarek J, Raniszewska A, Jahnz-Różyk K, et al. Effector memory T cells and CD45RO+ regulatory T cells in metastatic vs. non-metastatic lymph nodes in lung cancer patients. Front Immunol. 2022;13:864497.
Google Scholar
Lee SW, Choi HY, Lee GW, Kim T, Cho HJ, Oh IJ, et al. CD8(+) TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory: deciphering immunogenicity of tumor antigens. J Immunother Cancer. 2021;9:e002709.
Willinger T, Freeman T, Hasegawa H, McMichael AJ, Callan MF. Molecular signatures distinguish human central memory from effector memory CD8 T cell subsets. J Immunol. 2005;175:5895–903.
Google Scholar
Rangel Rivera GO, Knochelmann HM, Dwyer CJ, Smith AS, Wyatt MM, Rivera-Reyes AM, et al. Fundamentals of T cell metabolism and strategies to enhance cancer immunotherapy. Front Immunol. 2021;12:645242.
Google Scholar
Ray JP, Staron MM, Shyer JA, Ho PC, Marshall HD, Gray SM, et al. The interleukin-2-mTORc1 kinase axis defines the signaling, differentiation, and metabolism of T helper 1 and follicular B helper T cells. Immunity. 2015;43:690–702.
Google Scholar
Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002;16:769–77.
Google Scholar
Yang K, Shrestha S, Zeng H, Karmaus PW, Neale G, Vogel P, et al. T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity. 2013;39:1043–56.
Google Scholar
Scholz G, Jandus C, Zhang L, Grandclément C, López-Mejía IC, Soneson C, et al. Modulation of mTOR signalling triggers the formation of stem cell-like memory T cells. EBioMedicine. 2016;4:50–61.
Google Scholar
Li P, Li F, Zhang Y, Yu X, Li J. Metabolic diversity of tumor-infiltrating T cells as a target for anti-immune therapeutics. Cancer Immunol Immunother. 2023;72:3453–60.
Google Scholar
Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-term (≥5-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2025;43:2766–71.
Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells are preserved by IL-7 and IL-15. Blood. 2014;123:3750–9.
Google Scholar
Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, Manfredi F, et al. CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Investig. 2022;132:e150807.
Biasco L, Izotova N, Rivat C, Ghorashian S, Richardson R, Guvenel A, et al. Clonal expansion of T memory stem cells determines early anti-leukemic responses and long-term CAR T cell persistence in patients. Nat Cancer. 2021;2:629–42.
Google Scholar
Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang YK, et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629:201–10.
Google Scholar
Zhou X, Yu S, Zhao DM, Harty JT, Badovinac VP, Xue HH. Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. Immunity. 2010;33:229–40.
Google Scholar
Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293–300.
Google Scholar
Zuo S, Li C, Sun X, Deng B, Zhang Y, Han Y, et al. C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trial. Nat Commun. 2024;15:6155.
Google Scholar
Kasuya H, Zhang H, Ito Y, Yoshikawa T, Nakashima T, Li Y, et al. High CD62L expression predicts the generation of chimeric antigen receptor T cells with potent effector functions. Int Immunol. 2024;36:353–64.
Google Scholar
DeGolier KR, Danis E, D’Antonio M, Cimons J, Yarnell M, Kedl RM, et al. Antigen experience history directs distinct functional states of CD8+ CAR T cells during the antileukemia response. Nat Immunol. 2025;26:68–81.
Google Scholar
Konduri V, Joseph SK, Byrd TT, Nawas Z, Vazquez-Perez J, Hofferek CJ, et al. A subset of cytotoxic effector memory T cells enhances CAR T cell efficacy in a model of pancreatic ductal adenocarcinoma. Sci Transl Med. 2021;13:eabc3196.
Themeli M, Kloss CC, Ciriello G, Fedorov VD, Perna F, Gonen M, et al. Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol. 2013;31:928–33.
Google Scholar
Maeda T, Nagano S, Ichise H, Kataoka K, Yamada D, Ogawa S, et al. Regeneration of CD8αβ T cells from T-cell-derived iPSC imparts potent tumor antigen-specific cytotoxicity. Cancer Res. 2016;76:6839–50.
Google Scholar
Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, et al. Enhancing T cell receptor stability in rejuvenated iPSC-derived T cells improves their use in cancer immunotherapy. Cell Stem Cell. 2018;23:850–8.e4.
Google Scholar
Ueda T, Shiina S, Iriguchi S, Terakura S, Kawai Y, Kabai R, et al. Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nat Biomed Eng. 2023;7:24–37.
Google Scholar
Li S, Wang CS, Montel-Hagen A, Chen HC, Lopez S, Zhou O, et al. Strength of CAR signaling determines T cell versus ILC differentiation from pluripotent stem cells. Cell Rep. 2023;42:112241.
Google Scholar
Patsoukis N, Bardhan K, Weaver J, Herbel C, Seth P, Li L, et al. The role of metabolic reprogramming in T cell fate and function. Curr Trends Immunol. 2016;17:1–12.
Google Scholar
Chang CH, Curtis JD, Maggi LB Jr., Faubert B, Villarino AV, O’Sullivan D, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153:1239–51.
Google Scholar
Wu H, Zhao X, Hochrein SM, Eckstein M, Gubert GF, Knöpper K, et al. Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming. Nat Commun. 2023;14:6858.
Google Scholar
Cappabianca D, Pham D, Forsberg MH, Bugel M, Tommasi A, Lauer A, et al. Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence. Mol Ther Methods Clin Dev. 2024;32:101249.
Google Scholar
van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development. Immunity. 2012;36:68–78.
Google Scholar
Guerrero JA, Klysz DD, Chen Y, Malipatlolla M, Lone J, Fowler C, et al. GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency. Nat Commun. 2024;15:8658.
Google Scholar
Huang Y, Shao M, Teng X, Si X, Wu L, Jiang P, et al. Inhibition of CD38 enzymatic activity enhances CAR-T cell immune-therapeutic efficacy by repressing glycolytic metabolism. Cell Rep Med. 2024;5:101400.
Google Scholar
Shen L, Xiao Y, Zhang C, Li S, Teng X, Cui L, et al. Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with a less-differentiated phenotype and persistent antitumor activity. Cancer Lett. 2022;538:215710.
Google Scholar
Hope HC, de Sostoa J, Ginefra P, Andreatta M, Chiang YH, Ronet C, et al. Age-associated nicotinamide adenine dinucleotide decline drives CAR-T cell failure. Nat Cancer. 2025;6:1524–36.
Google Scholar
Xiao W, Wang RS, Handy DE, Loscalzo J. NAD(H) and NADP(H) redox couples and cellular energy metabolism. Antioxid Redox Signal. 2018;28:251–72.
Google Scholar
Jaccard A, Wyss T, Maldonado-Pérez N, Rath JA, Bevilacqua A, Peng JJ, et al. Reductive carboxylation epigenetically instructs T cell differentiation. Nature. 2023;621:849–56.
Google Scholar
Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood. 2013;121:573–84.
Google Scholar
Zarling S, Berenzon D, Dalai S, Liepinsh D, Steers N, Krzych U. The survival of memory CD8 T cells that is mediated by IL-15 correlates with sustained protection against malaria. J Immunol. 2013;190:5128–41.
Google Scholar
Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, et al. Rapid manufacturing of non-activated potent CAR T cells. Nat Biomed Eng. 2022;6:118–28.
Google Scholar
Wang SY, Scurti GM, Dalheim AV, Quinn S, Stiff PJ, Nishimura MI. Nonactivated and IL-7 cultured CD19-specific CAR T cells are enriched in stem cell phenotypes and functionally superior. Blood Adv. 2024;8:324–35.
Google Scholar
Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci USA. 2016;113:E7788–e97.
Google Scholar
Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov. 2017;7:1238–47.
Google Scholar
Hunter MR, Prosser ME, Mahadev V, Wang X, Aguilar B, Brown CE, et al. Chimeric γc cytokine receptors confer cytokine-independent engraftment of human T lymphocytes. Mol Immunol. 2013;56:1–11.
Google Scholar
Svoboda J, Landsburg DJ, Gerson J, Nasta SD, Barta SK, Chong EA, et al. Enhanced CAR T-cell therapy for lymphoma after previous failure. N Engl J Med. 2025;392:1824–35.
Google Scholar
Akbari B, Ghahri-Saremi N, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. Epigenetic strategies to boost CAR T cell therapy. Mol Ther. 2021;29:2640–59.
Google Scholar
Huang H, Baxter AE, Zhang Z, Good CR, Alexander KA, Chen Z, et al. Deciphering the role of histone modifications in memory and exhausted CD8 T cells. Sci Rep. 2025;15:17359.
Google Scholar
Gattinoni L, Speiser DE, Lichterfeld M, Bonini C. T memory stem cells in health and disease. Nat Med. 2017;23:18–27.
Google Scholar
Johnson JL, Georgakilas G, Petrovic J, Kurachi M, Cai S, Harly C, et al. Lineage-determining transcription factor TCF-1 initiates the epigenetic identity of T cells. Immunity. 2018;48:243–57.e10.
Google Scholar
Poorebrahim M, Lee H, Benaoudia S, Maity R, Ahn S, Leblay N, et al. Bclxl prevents progressive exhaustion in BCMA CAR T cells with maintenance of high TCF1-expressing T cells. Blood. 2023;142:454.
Google Scholar
Shan Q, Hu S, Chen X, Danahy DB, Badovinac VP, Zang C, et al. Ectopic Tcf1 expression instills a stem-like program in exhausted CD8(+) T cells to enhance viral and tumor immunity. Cell Mol Immunol. 2021;18:1262–77.
Google Scholar
Wu T, Ji Y, Moseman EA, Xu HC, Manglani M, Kirby M, et al. The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci Immunol. 2016;1:eaai8593.
Arias-Umana J, Markovska M, Chen Y, Zuern G, Grenier J, Hapke R, et al. 235 defining the role of TCF1 in CAR T cell memory and persistence. J ImmunoTher Cancer. 2024;12:A270–70.
Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, et al. TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion. Nature. 2019;571:211–8.
Google Scholar
Collins SM, Alexander KA, Lundh S, Dimitri AJ, Zhang Z, Good CR, et al. TOX2 coordinates with TET2 to positively regulate central memory differentiation in human CAR T cells. Sci Adv. 2023;9:eadh2605.
Google Scholar
Hyungseok S, Joyce C, Edahí G-A, Daniela S-C, Arundhoti D, Yueqiang HW, et al. TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion. Proc Natl Acad Sci USA. 2019;116:12410–5.
Google Scholar
Yoshikawa T, Wu Z, Inoue S, Kasuya H, Matsushita H, Takahashi Y, et al. Genetic ablation of PRDM1 in antitumor T cells enhances the therapeutic efficacy of adoptive immunotherapy. Blood. 2022;139:2156–72.
Google Scholar
Rutishauser RL, Martins GA, Kalachikov S, Chandele A, Parish IA, Meffre E, et al. Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties. Immunity. 2009;31:296–308.
Google Scholar
Jung IY, Narayan V, McDonald S, Rech AJ, Bartoszek R, Hong G, et al. BLIMP1 and NR4A3 transcription factors reciprocally regulate antitumor CAR T cell stemness and exhaustion. Sci Transl Med. 2022;14:eabn7336.
Google Scholar
Flinn IW, Jaeger U, Shah NN, Blaise D, Briones J, Shune L, et al. A first-in-human study of YTB323, a novel, autologous CD19-directed CAR-T cell therapy manufactured using the novel T-charge TM platform, for the treatment of patients (Pts) with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). Blood. 2021;138:740.
Google Scholar
Yang J, He J, Zhang X, Li J, Wang Z, Zhang Y, et al. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer J. 2022;12:104.
Google Scholar
Sperling AS, Derman BA, Nikiforow S, Im S-Y, Ikegawa S, Prabhala RH, et al. Updated phase I study results of PHE885, a T-charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with R/R multiple myeloma (RRMM). J Clin Oncol. 2023;41:8004.
Google Scholar
Michels A, Ho N, Buchholz CJ. Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms. Mol Ther. 2022;30:2401–15.
Google Scholar
Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024;221:e20230903.
Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375:91–6.
Google Scholar
Harrison S, Ho PJ, Lim S-L, Talam S, Pahl H, Dingar D, et al. Minimal residual disease (MRD)-negative outcomes following a novel, in vivo gene therapy generating anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cells in patients with relapsed and refractory multiple myeloma (RRMM): preliminary results from inMMyCAR, the first-in-human phase 1 study of KLN-1010. Blood. 2025;146:LBA-1.
Google Scholar
Liu C, Huang X, Chen KS, Xiong S, Yaremenko AV, Zhen X, et al. Systemic reprogramming of tumour immunity via IL-10-mRNA nanoparticles. Nat Nanotechnol. 2025;20:1526–38.
Gotoh H, Matsumoto Y. Cell-surface streptavidin fusion protein for rapid selection of transfected mammalian cells. Gene. 2007;389:146–53.
Google Scholar
Reinhard K, Rengstl B, Oehm P, Michel K, Billmeier A, Hayduk N, et al. An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020;367:446–53.
Google Scholar
Ma L, Dichwalkar T, Chang JYH, Cossette B, Garafola D, Zhang AQ, et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor. Science. 2019;365:162–8.
Google Scholar
Ma L, Hostetler A, Morgan DM, Maiorino L, Sulkaj I, Whittaker CA, et al. Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity. Cell. 2023;186:3148–65.e20.
Google Scholar
Andorko JI, Russell RM, Schnepp BC, Grubaugh D, Mullen KF, Wakabayashi A, et al. Targeted in vivo delivery of genetic medicines utilizing an engineered lentiviral vector platform results in CAR T and NK cell generation. Mol Ther. 2025;33:4937–52.
Du H, You X, Zhang J, Liu S, Zhou Y, Wang Y, et al. CAR macrophages engineered in vivo for attenuating myocardial ischemia-reperfusion injury. Circ Res. 2025;137:846–59.
Google Scholar
Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24:1499–503.
Google Scholar
Lei Z, Qingying S, Xin Z, Mengnian C, Dayu X, Yiwen S, et al. In vivo generation of CAR macrophages via the enucleated mesenchymal stem cell delivery system for glioblastoma therapy. Proc Natl Acad Sci USA. 2025;122:e2426724122.
Google Scholar
Martinez-Cibrian N, Español-Rego M, Pascal M, Delgado J, Ortiz-Maldonado V. Practical aspects of chimeric antigen receptor T-cell administration: from commercial to point-of-care manufacturing. Front Immunol. 2022;13:1005457.
Google Scholar
Lonez C, Breman E. Allogeneic CAR-T therapy technologies: has the promise been met? Cells. 2024;13:146.
Brudno JN, Somerville RP, Shi V, Rose JJ, Halverson DC, Fowler DH, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J Clin Oncol. 2016;34:1112–21.
Google Scholar
Jin X, Cao Y, Wang L, Sun R, Cheng L, He X, et al. HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation. Leukemia. 2020;34:909–13.
Google Scholar
Vasic D, Lee JB, Leung Y, Khatri I, Na Y, Abate-Daga D, et al. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities. Sci Immunol. 2022;7:eabl3642.
Google Scholar
Rotolo A, Caputo VS, Holubova M, Baxan N, Dubois O, Chaudhry MS, et al. Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting. Cancer Cell. 2018;34:596–610.e11.
Google Scholar
Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2017;23:2255–66.
Google Scholar
Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. “Off-the-shelf” allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185–99.
Google Scholar
van Duijn A, Van der Burg SH, Scheeren FA. CD47/SIRPα axis: bridging innate and adaptive immunity. J Immunother Cancer. 2022;10:e004589.
Perica K, Kotchetkov IS, Mansilla-Soto J, Ehrich F, Herrera K, Shi Y, et al. HIV immune evasin Nef enhances allogeneic CAR T cell potency. Nature. 2025;640:793–801.
Google Scholar
Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14:24–35.
Google Scholar
